hepat
c
viru
hcv
neutral
occur
region
epi
could
enhanc
antibodi
direct
specif
region
epii
remov
serum
sampl
persist
infect
patient
vaccin
chimpanze
phenomenon
socal
antibodi
interfer
show
type
interfer
observ
individu
immun
recombin
protein
one
hundr
twelv
blind
serum
sampl
phase
placebocontrol
dose
escal
trial
use
recombin
hcv
adjuv
healthi
hcvneg
adult
test
enzymelink
immunosorb
assay
bind
reactiv
peptid
repres
region
epi
epii
sampl
subsequ
test
neutral
activ
use
cellcultur
hcv
chimera
hcv
pseudotyp
particl
hcvpp
hcvpp
treatment
remov
epiispecif
antibodi
mock
treatment
control
peptid
among
serum
sampl
found
doubl
posit
epi
epii
epii
posit
epi
posit
doubl
neg
deplet
epii
antibodi
doubleposit
serum
sampl
increas
inhibitori
dose
id
neutral
antibodi
titer
sampl
p
contrast
id
neutral
titer
increas
doubleneg
sampl
p
addit
epispecif
antibodi
level
serum
sampl
show
signific
correl
id
neutral
titer
epii
antibodi
remov
p
conclus
data
show
antibodi
region
induc
immun
individu
recombin
protein
antibodi
mask
effect
neutral
activ
epispecif
antibodi
elicit
epiispecif
antibodi
interf
capac
avoid
produc
effect
crossneutr
vaccin
aim
hcv
envelop
protein
hepatolog
abbrevi
aa
amino
acid
elisa
enzymelink
immunosorb
assay
ffu
focu
form
unit
hcv
hepat
c
viru
hcvcc
cellcultur
hcv
hcvpp
pseudotyp
particl
hcv
hiv
human
immunodefici
viru
hypervari
region
id
inhibitori
dose
mab
monoclon
antibodi
od
optic
densiti
pb
phosphatebuff
salin
pn
positiveneg
ratio
rlu
rel
luciferas
unit
h
epat
c
viru
hcv
caus
chronic
infect
patient
despit
presenc
neutral
antibodi
overal
determin
individu
becom
infect
hcv
progress
seriou
endstag
liver
diseas
cirrhosi
hepatocellular
carcinoma
although
current
drug
therapi
clear
hcv
infect
treatment
success
limit
numer
factor
includ
access
care
cost
therapi
patient
adher
rel
efficaci
differ
regimen
side
effect
viral
genotyp
host
factor
also
unclear
whether
individu
protect
reinfect
drug
treatment
antibodybas
prophylaxi
success
prevent
hcv
recurr
liver
transplant
recipi
effect
vaccin
yet
develop
hcv
envelop
glycoprotein
repres
primari
target
vaccin
design
induc
neutral
antibodi
respons
clear
antibodi
surfac
protein
hcv
neutral
viru
vitro
vivo
recent
metaanalysi
chimpanze
vaccin
studi
show
increas
rate
clearanc
achiev
structur
protein
includ
vaccin
use
vitro
cellcultur
system
patient
plasma
sampl
monoclon
antibodi
mab
identifi
capabl
crossneutr
differ
genotyp
hcv
despit
role
neutral
antibodi
prevent
hcv
infect
mechan
also
exist
hcv
evas
neutral
respons
includ
genet
escap
polymorph
celltocel
spread
associ
lipoprotein
glycan
shield
surfac
protein
addit
presenc
interf
antibodi
recogn
hcv
region
amino
acid
aa
demonstr
sera
patient
chronic
infect
hcv
role
interf
antibodi
suggest
sever
viral
agent
addit
hcv
includ
influenza
human
immunodefici
viru
hiv
sever
acut
respiratori
syndrom
coronaviru
review
previou
work
interf
antibodi
bind
noncrit
bind
site
prevent
bind
neutral
antibodi
steric
hindranc
nonneutr
antibodi
caus
conform
chang
epitop
prevent
bind
neutral
antibodi
initi
presenc
interf
antibodi
hcv
shown
human
immun
globulin
use
pool
plasma
gener
antihcvposit
donor
two
epitop
epi
epii
studi
region
epi
span
amino
acid
region
previous
shown
contain
neutral
antibodi
epitop
highli
conserv
among
genotyp
antibodi
purifi
epii
aa
nonneutr
interf
neutral
activ
antibodi
direct
epi
data
confirm
interfer
sera
chimpanze
immun
recombin
protein
deplet
interf
antibodi
epii
increas
neutral
titer
chimer
cellcultur
hcv
hcvcc
reveal
crossneutr
activ
chimpanze
immun
sera
natur
antibodi
epii
still
discuss
neutral
murin
mab
map
region
encompass
aa
recent
studi
found
chronic
patient
immunoglobulin
fraction
affinitypurifi
linear
peptid
interfer
epi
neutral
antibodi
instead
work
addit
also
recent
character
murin
mab
high
neutral
activ
chimer
hcvcc
recogn
region
appear
region
induc
neutral
nonneutr
interf
antibodi
function
antibodi
associ
critic
residu
recogn
bind
recent
bifurc
mode
mab
action
epii
describ
involv
antibodi
interact
two
primari
anchor
site
epitop
hypothes
nonneutr
antibodi
bind
prefer
ahel
structur
epitop
wherea
neutral
antibodi
recogn
two
addit
amino
acid
region
studi
character
induct
neutral
antibodi
vaccin
individu
role
interf
antibodi
mask
neutral
activ
immun
sera
use
sampl
collect
phase
clinic
studi
dmid
clinicaltrialsgov
identifi
perform
saint
loui
univers
vaccin
treatment
evalu
unit
sponsor
nation
institut
allergi
infecti
diseas
random
doubleblind
placebocontrol
doseescal
vaccin
studi
assess
safeti
immunogen
recombin
hcv
adjuv
antibodi
whole
sever
linear
epitop
induc
immun
vaccin
also
found
elicit
crossneutr
antibodi
current
studi
found
antibodi
epitop
epi
aa
epii
aa
induc
immun
remov
epiispecif
antibodi
result
increas
neutral
activ
doubleposit
epi
epii
serum
sampl
patient
sampl
sampl
collect
phase
random
doubleblind
placebocontrol
studi
studi
registr
sixti
adult
enrol
three
group
sixteen
subject
per
group
receiv
lg
hcv
adjuv
administ
intramuscularli
week
subject
per
group
receiv
salin
placebo
biotinyl
peptid
enzymelink
immunosorb
assay
assay
perform
use
biotinyl
peptid
repres
known
linear
epitop
epi
epii
previous
describ
sera
test
dilut
cutoff
set
optic
densiti
od
neg
control
normal
human
serum
valu
express
positiveneg
ratio
pn
ratio
deplet
peptidespecif
antibodi
sera
peptidespecif
antibodi
deplet
sera
previous
describ
total
ng
biotinyl
peptid
epii
unrel
peptid
control
peptid
repres
protein
influenza
viru
mix
streptavidinco
magnet
dynabead
invitrogen
carlsbad
ca
block
nonspecif
bind
site
milk
phosphatebuff
salin
pb
bead
incub
human
serum
minut
room
temperatur
remov
peptidespecif
antibodi
bead
captur
magnet
supernat
collect
analysi
hcvcc
vitro
neutral
assay
hcvcc
chimer
viru
gener
previous
describ
region
base
consensu
sequenc
access
region
aa
hcv
polyprotein
share
homolog
genotyp
sequenc
use
phase
vaccin
studi
access
support
fig
neutral
antibodi
titer
determin
use
cell
perform
dilut
sera
mix
hcvcc
focu
form
unit
ffu
previous
describ
give
start
dilut
hour
cell
fix
formaldehyd
stain
antihcv
core
mous
mab
dilut
develop
diaminobenzidinestain
abc
kit
vector
laboratori
burlingam
ca
previous
describ
foci
count
use
autom
count
system
cellular
technolog
limit
cleveland
oh
use
biospot
softwar
assay
two
type
hcv
pseudotyp
particl
hcvpp
carri
envelop
protein
hcv
genotyp
access
access
gener
plasmid
lgml
obtain
nation
institut
health
aid
reagent
program
encod
firefli
luciferas
report
gene
lg
ml
encod
either
glycoprotein
cotransfect
cell
hour
posttransfect
supernat
cell
harvest
clarifi
lowspe
centrifug
minut
neg
control
pseudoparticl
without
envelop
protein
gener
neutral
antibodi
titer
determin
use
cell
describ
mix
sera
dilut
set
amount
hcvpp
rel
luciferas
unit
rlu
per
reaction
hcvpp
infect
perform
previous
describ
use
sampl
triplic
hour
media
remov
cell
lyse
freez
thaw
report
lysi
buffer
promega
madison
wi
twenti
microlit
use
determin
luciferas
activ
use
luciferas
assay
system
promega
read
use
luminomet
berthold
technolog
oak
ridg
tn
result
well
obtain
rlu
inhibitori
dose
id
neutral
titer
calcul
describ
titer
assign
sampl
inhibit
obtain
dilut
statist
analys
mockand
epiitr
sampl
compar
use
wilcoxon
signedrank
test
pair
data
correl
analysi
perform
use
graphpad
softwar
version
graphpad
softwar
inc
san
diego
ca
p
valu
consid
signific
vaccin
total
blind
sampl
test
enzymelink
immunosorb
assay
elisa
reactiv
peptid
repres
aa
epi
aa
epii
blind
sampl
also
treat
deplet
epii
antibodi
mock
treat
influenzaspecif
peptid
test
elisa
neutral
assay
complet
studi
sampl
unblind
statist
analyz
base
upon
treatment
group
reactiv
epi
epii
peptid
blind
panel
consist
sampl
vaccin
subject
placebo
subject
subject
repres
two
sampl
one
prevaccin
one
postvaccin
distribut
singleposit
doubleposit
doubleneg
sampl
group
preand
postplacebo
vaccin
shown
fig
within
placebo
group
preplacebo
sampl
test
neg
epitop
fig
wherea
two
postplacebo
sampl
demonstr
low
reactiv
epi
fig
among
prevaccin
sampl
six
test
posit
pn
epi
four
sampl
test
posit
epitop
fig
vaccin
reactiv
either
epitop
increas
significantli
p
fig
sampl
test
posit
least
one
epitop
fig
signal
chang
subject
show
prevaccin
reactiv
epi
epii
suggest
presenc
crossreact
antibodi
sampl
use
preand
postplacebo
prevaccin
sampl
n
calcul
elisa
specif
epi
epii
respect
frequenc
sampl
test
posit
epi
epii
postvaccin
correl
dose
vaccin
given
studi
fig
percentag
seroposit
sampl
base
upon
epi
epii
elisa
data
found
subject
immun
lg
hcv
subject
immun
lg
subject
immun
lg
deplet
epii
antibodi
serum
sampl
elisa
test
blind
sampl
classifi
posit
epi
epii
doubl
posit
six
posit
epii
posit
epi
neg
epitop
doubl
neg
address
whether
level
epi
epii
antibodi
influenc
neutral
activ
sera
treat
sampl
regardless
initi
elisa
result
epii
peptid
deplet
specif
antibodi
control
treat
sampl
parallel
influenzaspecif
peptid
sampl
test
mock
treat
epii
treat
epii
elisa
doubl
neg
n
initi
elisa
independ
treatment
group
doubleposit
sampl
treat
observ
signific
decreas
p
epiispecif
signal
compar
mocktreat
sampl
fig
also
observ
signific
decreas
epii
elisa
signal
p
six
sampl
test
posit
epii
fig
major
sampl
neg
epii
antibodi
elisa
epionli
posit
doubl
neg
also
show
decreas
epii
signal
fig
found
signific
p
epionlyposit
group
could
owe
presenc
sampl
low
level
epii
antibodi
class
posit
origin
elisa
analysi
owe
remov
sampl
background
antibodi
bound
epii
low
specif
neutral
titer
hcvcc
deplet
treatment
mockand
epiitr
sampl
test
neutral
assay
use
hcvcc
chimera
deplet
epii
antibodi
doubleposit
serum
sampl
increas
id
titer
sampl
p
fig
epiionlyposit
sampl
test
neutral
mock
epii
treatment
observ
slight
increas
id
titer
three
six
sampl
although
increas
found
nonsignific
p
fig
epionlyposit
sampl
also
observ
increas
id
titer
sampl
p
fig
although
p
valu
signific
analysi
suggest
trend
sampl
display
increas
neutral
sampl
neg
antibodi
epitop
sampl
test
duplic
serial
dilut
start
id
titer
repres
titer
calcul
neutral
viru
cell
cultur
sampl
display
less
neutral
activ
dilut
consid
nonneutr
assign
titer
analysi
purpos
statist
analysi
perform
use
wilcoxon
match
pair
signedrank
test
p
valu
consid
signific
neg
control
repres
normal
human
serum
posit
control
chimpanze
serum
sampl
previous
shown
contain
neutral
antibodi
id
titer
chimer
viru
id
titer
calcul
previous
describ
express
reciproc
dilut
calcul
neutral
viru
compar
foci
count
neg
control
titer
assign
sampl
inhibit
obtain
dilut
neutral
assay
perform
duplic
foci
consist
cell
count
posit
activ
could
indic
presenc
low
level
epii
antibodi
sampl
cutoff
initi
assay
doubleneg
sampl
fig
score
nonneutr
id
titer
treatment
epii
deplet
observ
increas
titer
sampl
test
triplic
follow
serial
dilut
start
id
titer
repres
titer
calcul
reduc
rlu
signal
compar
mocktreat
control
sampl
display
less
reduct
rlu
activ
dilut
consid
nonneutr
assign
titer
analysi
statist
analysi
perform
use
wilcoxon
match
pair
signedrank
test
p
valu
consid
signific
two
sampl
overal
chang
id
titer
group
signific
p
deplet
epii
antibodi
result
increas
neutral
titer
hcvpp
hypervari
region
region
lie
directli
upstream
epi
epitop
exclud
role
antibodi
interact
epiand
epiispecif
antibodi
perform
neutral
assay
use
hcvpp
carri
protein
access
hcvpp
carri
protein
access
sampl
test
antibodi
elisa
use
peptid
specif
sequenc
doubleposit
group
demonstr
highest
reactiv
peptid
support
fig
gener
observ
higher
id
titer
use
hcvpp
system
hcvcc
system
hcvpp
fig
howev
use
hcvpp
system
observ
similar
impact
id
titer
epii
antibodi
deplet
sera
regardless
whether
hcvpp
use
deplet
epii
antibodi
doubleposit
serum
sampl
increas
id
titer
sampl
p
hcvpp
fig
sampl
p
hcvpp
fig
similar
observ
hcvcc
id
titer
increas
observ
littl
chang
id
titer
epiionlyposit
sampl
hcvpp
p
respect
fig
epionlyposit
sampl
observ
slight
increas
id
titer
treat
sampl
fig
f
chang
found
signific
use
hcvpp
p
signific
use
hcvpp
p
consist
hcvcc
data
observ
signific
chang
id
titer
doubleneg
sera
epii
treatment
test
either
hcvpp
variant
data
shown
level
epi
epii
antibodi
correl
id
titer
mab
epii
region
previous
shown
neutral
sampl
chronic
infect
patient
also
shown
contain
neutral
antibodi
target
epitop
observ
decreas
id
titer
sampl
test
deplet
epii
peptid
suggest
antibodi
recogn
epitop
contribut
greatli
overal
neutral
activ
sampl
assess
whether
level
epi
epii
antibodi
associ
neutral
analyz
correl
id
titer
antibodi
level
peptid
mock
epii
treatment
sampl
classifi
antibodi
posit
either
epitop
first
perform
analysi
particl
hcvcc
hcvpp
clariti
data
shown
hcvcc
analysi
analys
perform
hcvpp
studi
return
similar
result
mocktreat
sampl
level
epi
epii
show
signific
correl
id
titer
fig
b
r
valu
analys
less
howev
treatment
epii
peptid
level
epi
antibodi
correl
significantli
id
titer
fig
p
r
spearman
correl
coeffici
r
wherea
reduc
antiepii
level
treat
sampl
correl
higher
lower
id
titer
despit
increas
id
titer
mani
sampl
fig
perform
analysi
hcvpp
found
signific
correl
epi
p
epii
p
antibodi
level
id
neutral
titer
mocktreat
sampl
fig
b
epii
antibodi
remov
observ
similar
increas
id
titer
correl
epi
antibodi
note
particl
fig
p
r
spearman
correl
coeffici
r
also
similar
observ
particl
reduc
epii
antibodi
level
treat
sampl
correl
significantli
higher
lower
id
titer
p
fig
data
suggest
level
epi
antibodi
strong
indic
neutral
capac
sampl
presenc
low
amount
epii
antibodi
subsequ
find
ask
whether
ratio
level
epi
epii
could
use
indic
neutral
abil
sampl
epiiepi
ratio
plot
id
titer
found
hcvcc
hcvpp
major
sampl
posit
neutral
activ
low
epiiepi
ratio
fig
howev
larg
number
sampl
low
ratio
display
detect
neutral
activ
result
reflect
complex
interact
epi
epii
antibodi
level
direct
comparison
titer
simpli
use
predict
neutral
capac
sampl
minimum
epi
antibodi
threshold
must
met
achiev
detect
neutral
develop
prophylact
vaccin
hcv
remain
challeng
current
data
suggest
would
advantag
includ
hcv
structur
protein
vaccin
circul
viru
infect
individu
exist
quasispeci
popul
variabl
throughout
genom
glycoprotein
exhibit
higher
level
variabl
among
genotyp
subtyp
thu
gener
antibodi
conserv
epitop
envelop
protein
would
benefici
develop
effect
vaccin
design
induc
neutral
antibodi
mab
recogn
conserv
epitop
locat
aa
within
epi
shown
inhibit
bind
crossneutr
antibodi
region
shown
induc
vaccin
natur
infect
time
antibodi
downstream
region
aa
also
induc
interfer
neutral
epi
antibodi
studi
blind
serum
sampl
deriv
phase
clinic
trial
healthi
volunt
support
hypothesi
antibodi
epii
could
interfer
neutral
activ
sera
also
contain
epi
antibodi
demonstr
use
cellcultur
viru
pseudotyp
virus
carri
hcv
envelop
genotyp
remov
epiispecif
antibodi
doubleposit
sera
result
increas
neutral
activ
sampl
p
fig
signific
chang
neutral
observ
sampl
posit
epii
sampl
neg
epitop
observ
increas
neutral
activ
epionlyposit
sampl
becam
signific
p
use
hcvpp
fig
could
owe
low
amount
epiand
epiispecif
antibodi
present
sampl
juxtaposit
region
epi
could
potenti
impact
epii
interf
effect
antibodi
present
studi
use
hcvpp
indic
case
observ
similar
effect
epii
treatment
id
titer
use
hcvpp
use
hcvcc
hcvpp
doubleposit
sampl
treat
studi
eight
display
increas
neutral
activ
treatment
remain
neg
neutral
antibodi
howev
sampl
contain
highest
ratio
epiiepi
antibodi
could
indic
threshold
antibodi
ratio
need
achiev
neutral
andor
epispecif
antibodi
nonneutr
sampl
investig
concept
epiiepi
antibodi
ratio
although
neutral
activ
serum
sampl
associ
low
ratio
absolut
correl
fig
suggest
morecomplex
interact
exist
antibodyantigen
pair
may
determin
neutral
serum
sampl
interfer
epi
epii
antibodi
support
signific
correl
epi
antibodi
titer
id
neutral
titer
epii
antibodi
remov
sampl
fig
use
hcvcc
hcvpp
system
found
lack
correl
level
epii
neutral
fig
suggest
antibodi
epii
induc
vaccin
contribut
greatli
overal
neutral
activ
sampl
find
signific
correl
epii
antibodi
level
neutral
use
hcvpp
system
fig
could
owe
higher
level
antibodi
antibodi
present
sampl
epii
signal
act
indic
better
immun
respons
vaccin
correl
longer
observ
epii
treatment
fig
treatment
result
greater
number
sampl
increas
id
titer
low
epii
signal
oppos
sampl
low
epii
signal
lose
neutral
abil
overal
find
direct
correl
antiepii
antibodi
level
neutral
system
use
therefor
conclud
epiispecif
antibodi
induc
vaccin
recombin
protein
bind
distinct
residu
region
could
result
interf
phenotyp
instead
neutral
phenotyp
contrast
number
public
show
antibodi
direct
region
inhibit
viral
infect
residu
within
region
involv
bind
howev
previou
studi
also
shown
function
qualiti
antibodi
differ
depend
upon
specif
epitop
recogn
critic
bind
residu
major
neutral
activ
detect
assay
appear
associ
epispecif
antibodi
consist
previou
report
crossneutr
sampl
phase
clinic
trial
given
epi
region
highli
conserv
genotyp
recent
subset
sampl
cohort
shown
bind
competit
crossneutr
mab
recogn
residu
within
epi
well
residu
locat
elsewher
support
crossneutr
potenti
vaccin
sampl
test
crossneutr
activ
genotyp
possibl
studi
use
treat
sera
owe
limit
amount
serum
sampl
sequenc
region
use
cellcultur
chimer
viru
differ
slightli
use
recombin
vaccin
support
fig
greatest
variat
locat
least
part
neutral
activ
serum
sampl
previous
shown
direct
observ
significantli
higher
id
titer
use
hcvpp
compar
hcvpp
exclud
interact
antibodi
epi
antibodi
neutral
possibl
antibodi
recogn
region
act
synergist
addit
could
compet
bind
neutral
given
posit
epitop
analys
complex
although
import
understand
mechan
hcv
neutral
polyclon
sera
beyond
scope
studi
mechan
epii
antibodi
interfer
still
elucid
given
epi
epii
adjac
hcv
protein
interfer
could
therefor
occur
steric
hindranc
prevent
bind
epispecif
antibodi
conform
chang
induc
bind
epii
interestingli
structur
studi
shown
epii
epi
could
adopt
differ
conform
indic
structur
flexibl
site
protein
flexibl
confirm
crystal
structur
hcv
complex
structur
interact
occur
region
downstream
nterminu
encompass
epi
epii
region
part
epii
region
shown
form
part
conform
epitop
recogn
broadli
neutral
antibodi
structur
studi
confirm
epitop
includ
portion
receptorbind
loop
could
account
epiispecif
antibodi
exhibit
neutral
activ
presenc
altern
conform
virion
could
chang
specif
andor
affin
antibodi
recognit
two
epitop
thu
constitut
strategi
hcv
evad
humor
immun
respons
altern
epiispecif
antibodi
could
enhanc
infect
could
compet
neutral
effect
antibodi
includ
epi
data
seem
support
mechan
given
invers
correl
level
epii
antibodi
neutral
fig
remov
epii
antibodi
epiionlyposit
group
sampl
result
signific
increas
neutral
activ
p
fig
howev
sampl
size
small
n
provid
suffici
statist
power
remov
epii
antibodi
result
increas
id
titer
subset
sampl
foci
number
rlu
signal
analyz
respect
epiiantibodi
level
observ
increas
foci
rlu
associ
increas
amount
epii
data
shown
indic
epiispecif
antibodi
induc
vaccin
enhanc
viral
infect
overal
studi
shown
antibodi
epitop
epi
epii
induc
vaccin
recombin
protein
induct
antibodi
dose
depend
group
patient
receiv
highest
dose
vaccin
lg
contain
highest
number
doubleposit
sampl
compar
lowestdos
group
receiv
lg
doubl
posit
number
analys
use
sampl
deplet
epiispecif
antibodi
show
signific
effect
antibodi
neutral
activ
epispecif
antibodi
hcvcc
hcvpp
system
support
previou
hypothesi
antibodi
epii
interfer
function
antibodi
epi
given
crossneutr
potenti
antibodi
epi
prevent
induct
antibodi
epii
interfer
activ
may
lead
improv
qualiti
efficaci
futur
hcv
vaccin
